Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells

Figure 1

Sec62 is a prognostic marker for NSCLC patients. A, Patients with rSec62 < 2.1 exhibited significantly longer survival compared with those with rSec62 ≥ 2.1 (P < 0.001). B, The survival benefit of a low Sec62 protein level in the lung cancer tissue was significant in patients with SCC (P < 0.001). C, The survival benefit was not significant in patients with AC (P = 0.054).

Back to article page